Elizabeth A Mittendorf1, Karla V Ballman2, Linda M McCall2, Min Yi2, Aysegul A Sahin2, Isabelle Bedrosian2, Nora Hansen2, Sheryl Gabram2, Thelma Hurd2, Armando E Giuliano2, Kelly K Hunt2. 1. Elizabeth A. Mittendorf, Min Yi, Aysegul A. Sahin, Isabelle Bedrosian, and Kelly K. Hunt, The University of Texas MD Anderson Cancer Center, Houston; Thelma Hurd, The University of Texas at San Antonio, San Antonio, TX; Karla V. Ballman, Mayo Clinic, Rochester, MN; Linda M. McCall, Duke University, Durham, NC; Nora Hansen, Northwestern University, Chicago, IL; Sheryl Gabram, Emory University, Atlanta, GA; Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, CA. eamitten@mdanderson.org. 2. Elizabeth A. Mittendorf, Min Yi, Aysegul A. Sahin, Isabelle Bedrosian, and Kelly K. Hunt, The University of Texas MD Anderson Cancer Center, Houston; Thelma Hurd, The University of Texas at San Antonio, San Antonio, TX; Karla V. Ballman, Mayo Clinic, Rochester, MN; Linda M. McCall, Duke University, Durham, NC; Nora Hansen, Northwestern University, Chicago, IL; Sheryl Gabram, Emory University, Atlanta, GA; Armando E. Giuliano, Cedars-Sinai Medical Center, Los Angeles, CA.
Abstract
PURPOSE: The seventh edition of the American Joint Committee on Cancer (AJCC) staging system for breast cancer differentiates patients with T1 tumors and lymph node micrometastases (stage IB) from patients with T1 tumors and negative nodes (stage IA). This study was undertaken to determine the utility of the stage IB designation. PATIENTS AND METHODS: The following two cohorts of patients with breast cancer were identified: 3,474 patients treated at The University of Texas MD Anderson Cancer Center from 1993 to 2007 and 4,590 patients from the American College of Surgeons Oncology Group (ACOSOG) Z0010 trial. Clinicopathologic and outcomes data were recorded, and disease was staged according to the seventh edition AJCC staging system. Recurrence-free survival (RFS), disease-specific survival (DSS), and overall survival (OS) were determined using the Kaplan-Meier method and compared using the log-rank test. RESULTS: Median follow-up times were 6.1 years and 9.0 years for the MD Anderson Cancer Center and ACOSOG cohorts, respectively. In both cohorts, there were no significant differences between patients with stage IA and stage IB disease in 5- or 10-year RFS, DSS, or OS. Estrogen receptor (ER) status and grade significantly stratified patients with stage I disease with respect to RFS, DSS, and OS. CONCLUSION: Among patients with T1 breast cancer, individuals with micrometastases and those with negative nodes have similar survival outcomes. ER status and grade are better discriminants of survival than the presence of small-volume nodal metastases. In preparing the next edition of the AJCC staging system, consideration should be given to eliminating the stage IB designation and incorporating biologic factors.
PURPOSE: The seventh edition of the American Joint Committee on Cancer (AJCC) staging system for breast cancer differentiates patients with T1 tumors and lymph node micrometastases (stage IB) from patients with T1 tumors and negative nodes (stage IA). This study was undertaken to determine the utility of the stage IB designation. PATIENTS AND METHODS: The following two cohorts of patients with breast cancer were identified: 3,474 patients treated at The University of Texas MD Anderson Cancer Center from 1993 to 2007 and 4,590 patients from the American College of Surgeons Oncology Group (ACOSOG) Z0010 trial. Clinicopathologic and outcomes data were recorded, and disease was staged according to the seventh edition AJCC staging system. Recurrence-free survival (RFS), disease-specific survival (DSS), and overall survival (OS) were determined using the Kaplan-Meier method and compared using the log-rank test. RESULTS: Median follow-up times were 6.1 years and 9.0 years for the MD Anderson Cancer Center and ACOSOG cohorts, respectively. In both cohorts, there were no significant differences between patients with stage IA and stage IB disease in 5- or 10-year RFS, DSS, or OS. Estrogen receptor (ER) status and grade significantly stratified patients with stage I disease with respect to RFS, DSS, and OS. CONCLUSION: Among patients with T1 breast cancer, individuals with micrometastases and those with negative nodes have similar survival outcomes. ER status and grade are better discriminants of survival than the presence of small-volume nodal metastases. In preparing the next edition of the AJCC staging system, consideration should be given to eliminating the stage IB designation and incorporating biologic factors.
Authors: Gary H Lyman; Armando E Giuliano; Mark R Somerfield; Al B Benson; Diane C Bodurka; Harold J Burstein; Alistair J Cochran; Hiram S Cody; Stephen B Edge; Sharon Galper; James A Hayman; Theodore Y Kim; Cheryl L Perkins; Donald A Podoloff; Visa Haran Sivasubramaniam; Roderick R Turner; Richard Wahl; Donald L Weaver; Antonio C Wolff; Eric P Winer Journal: J Clin Oncol Date: 2005-09-12 Impact factor: 44.544
Authors: Lisa A Carey; Charles M Perou; Chad A Livasy; Lynn G Dressler; David Cowan; Kathleen Conway; Gamze Karaca; Melissa A Troester; Chiu Kit Tse; Sharon Edmiston; Sandra L Deming; Joseph Geradts; Maggie C U Cheang; Torsten O Nielsen; Patricia G Moorman; H Shelton Earp; Robert C Millikan Journal: JAMA Date: 2006-06-07 Impact factor: 56.272
Authors: T Sørlie; C M Perou; R Tibshirani; T Aas; S Geisler; H Johnsen; T Hastie; M B Eisen; M van de Rijn; S S Jeffrey; T Thorsen; H Quist; J C Matese; P O Brown; D Botstein; P E Lønning; A L Børresen-Dale Journal: Proc Natl Acad Sci U S A Date: 2001-09-11 Impact factor: 11.205
Authors: P L Fitzgibbons; D L Page; D Weaver; A D Thor; D C Allred; G M Clark; S G Ruby; F O'Malley; J F Simpson; J L Connolly; D F Hayes; S B Edge; A Lichter; S J Schnitt Journal: Arch Pathol Lab Med Date: 2000-07 Impact factor: 5.534
Authors: C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein Journal: Nature Date: 2000-08-17 Impact factor: 49.962
Authors: T M Breslin; L Cohen; A Sahin; J B Fleming; H M Kuerer; L A Newman; E S Delpassand; R House; F C Ames; B W Feig; M I Ross; S E Singletary; A U Buzdar; G N Hortobagyi; K K Hunt Journal: J Clin Oncol Date: 2000-10-15 Impact factor: 44.544
Authors: Paul L Nguyen; Alphonse G Taghian; Matthew S Katz; Andrzej Niemierko; Rita F Abi Raad; Whitney L Boon; Jennifer R Bellon; Julia S Wong; Barbara L Smith; Jay R Harris Journal: J Clin Oncol Date: 2008-04-14 Impact factor: 44.544
Authors: Laura A Lambert; Gregory D Ayers; Rosa F Hwang; Kelly K Hunt; Merrick I Ross; Henry M Kuerer; S Eva Singletary; Gildy V Babiera; Frederick C Ames; Barry Feig; Anthony Lucci; Savitri Krishnamurthy; Funda Meric-Bernstam Journal: Ann Surg Oncol Date: 2006-02-10 Impact factor: 5.344
Authors: Jacqueline S Jeruss; Elizabeth A Mittendorf; Susan L Tucker; Ana M Gonzalez-Angulo; Thomas A Buchholz; Aysegul A Sahin; Janice N Cormier; Aman U Buzdar; Gabriel N Hortobagyi; Kelly K Hunt Journal: J Clin Oncol Date: 2007-12-03 Impact factor: 44.544
Authors: Tamer M Fouad; Angelica M Gutierrez Barrera; James M Reuben; Anthony Lucci; Wendy A Woodward; Michael C Stauder; Bora Lim; Sarah M DeSnyder; Banu Arun; Babiera Gildy; Vicente Valero; Gabriel N Hortobagyi; Naoto T Ueno Journal: Lancet Oncol Date: 2017-04 Impact factor: 41.316
Authors: Natalia S Tucker; Amy E Cyr; Foluso O Ademuyiwa; Adel Tabchy; Krystl George; Piyush K Sharma; Linda X Jin; Souzan Sanati; Rebecca Aft; Feng Gao; Julie A Margenthaler; William E Gillanders Journal: Ann Surg Date: 2016-12 Impact factor: 12.969
Authors: Anna Weiss; Mariana Chavez-MacGregor; Daphne Y Lichtensztajn; Min Yi; Audree Tadros; Gabriel N Hortobagyi; Sharon H Giordano; Kelly K Hunt; Elizabeth A Mittendorf Journal: JAMA Oncol Date: 2018-02-01 Impact factor: 31.777
Authors: R K Charaghvandi; B van Asselen; M E P Philippens; H M Verkooijen; C H van Gils; P J van Diest; R M Pijnappel; M G G Hobbelink; A J Witkamp; T van Dalen; E van der Wall; T C van Heijst; R Koelemij; M van Vulpen; H J G D van den Bongard Journal: BMC Cancer Date: 2017-03-09 Impact factor: 4.430